Drug Combination Details
General Information of the Combination (ID: C49133) | |||||
---|---|---|---|---|---|
Name | Epigallocatechin gallate NP Info | + | Celecoxib Drug Info | ||
Structure | + | ||||
Disease |
Pancreatic cancer
[ICD-11: 2C10]
|
Investigative | [1] |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. Enhancing Drug Efficacy by This Combination | ||||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Experiment 1 Reporting the Effect of This Combination | [1] | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | IL6 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | MMP-2 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | VEGFA | Molecule Info |
Pathway MAP
|
||
In-vitro Model | COLO 357 | CVCL_0221 | Pancreatic adenosquamous carcinoma | Homo sapiens | ||
Experimental
Result(s) |
EGCG synergistically boosts celecoxib-mediated effects and reduces the levels of celecoxib required to elicit beneficial effects on tumorigenic mediators by a factor of ten. |